Page 16 - Sun Pharma

Sun Pharma shares dip 4%, m-cap drops by Rs 5,065 cr as Q2 net declines 59%

The scrip was the worst hit among the 30 Sensex blue chips

Sun Pharma profit slips 59%

Sun Pharma reported a decline in consolidated net profit in the second quarter of FY 2018

Sun Pharma Q2 net plunges 59% at Rs 912 cr

Analysts on average had expected a profit of Rs 827 crore, according to Thomson Reuters data

Sun Pharma: Taro provides some respite

Key triggers are in improvement in ex-Taro performance, resolution of US FDA issues

Sun Pharma, Dr Reddy's, Glenmark gain even after price-fixing charges in US

Nifty Pharma index, the largest gainer among sectoral indices, was up 2.8%, as compared to unchanged in Nifty 50 index at 10,441 at 09:46 AM

Pharma shares in focus; Sun Pharma gains 4% in intra-day deals

Sun Pharma, Unichem Lab, Ipca Lab, Wockhardt, Marksans Pharma, Cadila Healthcare and Aurobindo Pharma were up in the range of 3% to 8%

Sun Pharma gets USFDA nod for generic drug to treat cardiac problems

As per IMS, Coreg CR had annual sales of around $208 million in the US for the 12 months ended August 2017

Sun Pharma gains 4% as Dadra plant gets EIR from USFDA

The stock was up 4% to Rs 549 on the BSE in early morning trade in otherwise subdued market.

US FDA clears Sun Pharma's Dadra plant

Dadra is Sun Pharma's second-largest plant in India, and had received 11 adverse observations in a US FDA inspection in April

Sun Pharmaceutical gets USFDA inspection report for Dadra facility

The Mumbai based pharma major however did not share the details of the EIR

Sun Pharmaceutical, Dr Reddy's line up new drugs amid price war

Arm themselves with speciality and complex drugs facing less competition

Speciality segment a key growth driver: Sun Pharma

The company's speciality initiatives target the global market with the US being one of the important markets, Shanghvi said

Pharma shares extend gain; Sun Pharma, Divi's Lab up over 10% in three days

In past three trading sessions, Nifty Pharma index surged 6%, while S&P BSE Healthcare gain 5% against 1% rise in the benchmark indices.

More pressure ahead for Sun Pharma stock

Significant price erosion in the US market and lack of triggers, product pipeline are key worries

Sun Pharma expects FY18 revenues to decline due to pricing pressure in US

Firm plans to spend up to 10% of its revenues on R&D activities

Sun Pharma stares at sharp earnings downgrades

A muted revenue outlook and higher costs will keep margins and earnings under pressure in FY18

Sun Pharma slips to Rs 424 cr Q1 loss on weak sales, anti-trust settlement

An one-off Rs 950 crore payment to settle an anti trust litigation coupled with weak performance in core India and US markets resulted in Sun Pharmaceutical Industries posting Rs 424 crore loss in first quarter FY 2018. In same period last year the company had posted a profit of Rs 2037 crore. Revenue dipped 23 per cent to Rs 6167 crore owing to continued pricing pressure in the US, regulatory challenges and GST-led de stocking in the domestic market. Domestic sales declined 5 per cent while US market revenue was down 42 per cent. The company's US subsidiary has seen 30 per cent decline in sales on a year on year basis. Also the first quarter sales in last fiscal had a high base impact owing to the as the six months exclusivity in sale of anti-leukemia drug Gleevec. Overall pricing pressure also impacted the growth. Profit before tax and exceptional items fell 70 per cent to Rs 791 crore. A Rs 950 crore outgo to settle a litigation in the US dragged the company to loss.Sun Pharma ...

Sun Pharma, 10 others settle insider trading case with Sebi

Sebi's High Powered Advisory Committee recommended the case for settlement on the payment of Rs 18 L

Sun Pharma posts net loss of Rs 425 cr in Q1 on one-off charge

US sales drop 42%; Rs 950-cr charge related to settlement of antitrust case in US

39 stocks from BSE 500 index hit 52-week lows

Tata Motors, Sun Pharma, Dr Reddy's Lab, Coal India and Amara Raja Batteries hit 52-week lows